While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Earlier last year, a daily-pill version of Novo's amycretin was shown to lead to 13.1% weight loss after just 12 weeks, boosting its shares. Novo said in September it planned to decide on further ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Danish weight-loss drug maker Novo Nordisk (NVO) is jumping 5% after the company reported higher-than-expected net income for ...

Novo Nordisk shares ... Details about its next-generation weight loss drugs CagriSema and amycretin are also in focus. It's been a rocky few months for Novo Nordisk. Prescription data from IQVIA ...

Novo Nordisk's stock (NVO ... The highest dose, 20 mg, provided the highest weight loss. Novo is also testing a pill with the same formula, which had disappointing results in early-stage trials ...

Senators questioned Novo Nordisk CEO Lars Jørgensen on Tuesday ... in Spain that shows significant potential for weight loss that comes in pill form. A new study finds the drug semaglutide ...

Learn More » Last week, Novo Nordisk released its year-end results ... The company has, however, been working on a weight loss pill, which could be a game-changer for the market.